What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Internal medicine
His primary areas of study are Multiple myeloma, Internal medicine, Surgery, Bortezomib and Lenalidomide.
His Multiple myeloma research is multidisciplinary, relying on both Cancer research, Survival rate, Dexamethasone, Pharmacology and Transplantation.
His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Oncology.
His Surgery study integrates concerns from other disciplines, such as Intensive care medicine, Plasma cell neoplasm and Risk factor.
His studies in Bortezomib integrate themes in fields like Proteasome inhibitor, Tolerability, Macroglobulinemia and Melphalan.
Much of his study explores Lenalidomide relationship to Thalidomide.
His most cited work include:
- Initial genome sequencing and analysis of multiple myeloma (1090 citations)
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma (833 citations)
- Genetics and Cytogenetics of Multiple Myeloma A Workshop Report (608 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Multiple myeloma, Internal medicine, Lenalidomide, Bortezomib and Surgery.
His Multiple myeloma research includes elements of Regimen, Cancer research and Transplantation.
His research investigates the link between Cancer research and topics such as Molecular biology that cross with problems in Gene expression, Cytotoxic T cell and Fluorescence in situ hybridization.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Oncology.
The concepts of his Lenalidomide study are interwoven with issues in Tolerability, Randomized controlled trial and Neutropenia.
His study in Bortezomib is interdisciplinary in nature, drawing from both Proteasome inhibitor, Refractory and Pharmacology.
He most often published in these fields:
- Multiple myeloma (60.06%)
- Internal medicine (46.65%)
- Lenalidomide (24.58%)
What were the highlights of his more recent work (between 2016-2021)?
- Multiple myeloma (60.06%)
- Internal medicine (46.65%)
- Oncology (18.72%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Multiple myeloma, Internal medicine, Oncology, Cancer research and Bortezomib.
His work carried out in the field of Multiple myeloma brings together such families of science as Molecular biology and Cereblon.
His research in Oncology focuses on subjects like Disease, which are connected to Cohort study.
In his work, Kinase is strongly intertwined with Cell culture, which is a subfield of Cancer research.
His Bortezomib research incorporates elements of Clinical trial and Proteasome.
His work deals with themes such as Gastroenterology, Cyclophosphamide and Urology, which intersect with Dexamethasone.
Between 2016 and 2021, his most popular works were:
- Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. (149 citations)
- A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis (125 citations)
- Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (110 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
A. Keith Stewart mainly investigates Multiple myeloma, Internal medicine, Oncology, Bortezomib and Lenalidomide.
His Multiple myeloma study incorporates themes from Molecular biology, Cancer research, Gene rearrangement and Stem cell.
His Oncology study combines topics in areas such as Survival rate, Surgery and Disease.
His Bortezomib research is multidisciplinary, incorporating perspectives in Clinical trial, Autologous stem-cell transplantation, CRISPR and Macroglobulinemia.
His studies examine the connections between Lenalidomide and genetics, as well as such issues in Adverse effect, with regards to Discontinuation and Post-hoc analysis.
His studies deal with areas such as Gastroenterology and Neutropenia as well as Pomalidomide.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
